Valneva completes recruitment for Phase 3 Lot-to-Lot Consistency Trial of its Chikungunya Vaccine Candidate
Valneva, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet... View Article
Valneva completes Phase 3 trial recruitment for its inactivated COVID-19 vaccine candidate
Valneva , a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant... View Article
New member | Learn & Go
Kaligo digital learning book, initially dedicated to early childhood, is based on the stages of the active learning approach: production... View Article
Nantes > Kathmandu: a clinical trial for ORTHOPUS mechanical prostheses
For several months, Orthopus has been preparing a clinical trial for our set of upper-limb mechanical prostheses . Thanks to... View Article
Responsible innovation should supersede the precautionary approach
Interview with Franck Zal, the founder of Hemarina, Vice-president of Atlanpole Biotherapies President of a biotech firm that develops “oxygen... View Article
New member | Amossys
Audit, consulting, evaluation of security products, training, incident response, R&D… In order to help our customer secure their digital environment,... View Article
New member | NeuroKyma
PROVIDER OF ADVANCED TECHNOLOGY FOR PREDICTIVE ANALYSIS ON CNS TRIALS DISEASES AT THE CROSSING OF E-HEALTH AND NEURO-IMAGING Our mission is... View Article
XENOTHERA signs a pre-order contract of its anti-COVID treatment with the French government
XENOTHERA announces the signature of a contract to reserve 30,000 unit doses of XAV-19 with the French Ministry of Health... View Article
GlioCure expands its know-how and technological offer to nanovectors
GlioCure SA, a biotechnology company specializing in neuro-oncology, announces the launch of Cure’nCaps Solutions (www.curencaps.com), a platfom for the formulation... View Article
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations. CoVepiT is a... View Article